Abbott Laboratories (ABT)
NYSE:ABT
Want to see ABT full AI Analyst Report?
ABT Stock Chart & Stats
$96.81
-$0.27(-0.24%)
At close: 4:00 PM EST
$96.81
-$0.27(-0.24%)
Day’s Range― - ―
52-Week Range$99.05 - $139.06
Previous CloseN/A
Volume1.03M
Average Volume (3M)11.63M
Market Cap
$176.88B
Enterprise Value$174.80B
Total Cash (Recent Filing)$8.94B
Total Debt (Recent Filing)$15.07B
Price to Earnings (P/E)33.5
Beta0.28
Next Earnings
Jul 16, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend Yield1.88%
Share Statistics
EPS (TTM)1.15
Shares Outstanding1,741,657,300
10 Day Avg. Volume8,896,059
30 Day Avg. Volume11,627,532
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit7.10
Enterprise Value/Ebitda15.03
Forecast
1Y Price Target
$126.59Price Target Upside30.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)5.6
Revenue Forecast (FY)$50.06B
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Market ExpansionFavorable clinical trial outcomes and positive feedback on next-generation left atrial appendage closure devices may accelerate adoption, support broader reimbursement, and strengthen competitive positioning in the LAAC market.
Product PipelineUpcoming device launches such as the Volt pulsed field ablation system and a combined glucose‑ketone sensor could expand market share and drive meaningful revenue growth in the medical devices segment.
Reporting ComparabilityPresentation of comparable revenue that counts acquisition-related sales in both periods and excludes currency and one-time items should improve transparency and help investors better evaluate organic performance.
Bears Say
Balance Sheet LeverageThe acquisition was funded mainly with new senior debt, increasing leverage and potentially limiting financial flexibility if expected cost synergies remain modest.
Regulatory And Quality RisksFDA inspection findings around Libre sensor testing and validation, including releases without final accuracy testing, create regulatory and manufacturing risks that could require remediation and disrupt supply.
Respiratory Demand WeaknessA weaker influenza season and softer respiratory virus demand reduce sales expectations for the respiratory business and can weigh on overall diagnostics revenue.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $99.05 and its highest was $139.06 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $176.88B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jul 16, 2026 which is in 88 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Apr 16, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.145 by $0.005.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.59 which represents an annual dividend yield of 1.88%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.29.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,741,657,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.15 in its last earnings report, beating expectations of $1.145. Following the earnings report the stock price went down -5.996%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$126.59 (30.76% Upside)
$126.59 (30.76% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 94%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $379.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Bearish
Bullish news 40%
Bearish news 60%
Bearish news 60%
Company Description
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
ABT Company Deck
ABT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook driven by solid device performance, completion and strategic value of the Exact Sciences acquisition (adding ~$3 billion of sales), strong pipeline progress, and underlying comparable sales and EPS growth. However, near-term headwinds remain: a notably weak respiratory season that hit molecular testing, ongoing Nutrition volume recovery, China VBP lingering effects, and modest EPS dilution from the acquisition. Management emphasized confidence in execution and an expectation of growth acceleration in the second half of the year, balancing near-term caution with medium- to long-term upside.View all ABT earnings summariesABT Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other
ABT Stock 12 Month Forecast
Average Price Target
$126.59
▲(30.76% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
25.01% Mutual Funds
0.23% Other Institutional Investors
51.06% Public Companies and Individual Investors